Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 3/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 2/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30500935 | 1.00 | SYK (0.70) | SYKMAPTSMN1; SMN2LMNAIDO1 | |
| SCHEMBL7026898 | 1.00 | SYK (0.70) | SYKMAPTSMN1; SMN2LMNAIDO1 | |
| SCHEMBL31236564 | 0.96 | SYK (0.65) | SYKMAPTSMN1; SMN2LMNAIDO1 | |
| SCHEMBL13480455 | 0.91 | SYK (0.66) | SYKMAPTSMN1; SMN2LMNAIDO1 | |
| SCHEMBL31236485 | 0.90 | SYK (0.58) | SYKMAPTSMN1; SMN2LMNAIDO1 | |
| SCHEMBL5019087 | 0.89 | LMNA (0.61) | SYKSMN1; SMN2LMNAHTTALDH1A1 | |
| SCHEMBL6180043 | 0.88 | SYK (0.62) | SYKMAPTIDO1ALDH1A1CTSS | |
| SCHEMBL31236541 | 0.88 | SYK (0.59) | SYKMAPTSMN1; SMN2LMNAIDO1 | |
| SCHEMBL7022981 | 0.88 | SYK (0.68) | SYKMAPTSMN1; SMN2LMNAIDO1 | |
| SCHEMBL13480420 | 0.87 | SYK (0.60) | SYKMAPTCTSSPPARACTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4074709-A1 | MONOCYCLIC BETA-LACTAM COMPOUND AND USE THEREOF | Evopoint Biosciences Co., Ltd. (CN) | 2022-10-19 | — | — | EP | disclosed |
| CN-108778273-B | Bicyclic aryl monocyclic beta-lactam compounds and methods of use thereof for treating bacterial infections | 默沙东公司 | 2022-06-17 | — | — | CN | disclosed |
| EP-1976849-B1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | MERCK SHARP & DOHME (US) | 2016-03-09 | — | — | EP | disclosed |
| US-7879890-B2 | hydantoin derivatives that can inhibit matrix metalloproteinases and tumor necrosis factor alpha-converting enzyme, to prevent the release of tumor necrosis factor; treatment of septic shock, reperfusion injuries, meningitis, psoriasis, arthritis, inflammatory bowel disease and ankylosing spondylitis | SCHERING CORPORATION (US) | 2011-02-01 | — | — | US | disclosed |
| EP-1778676-B1 | HYDANTOIN DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORP (US) | 2010-08-25 | — | — | EP | disclosed |
| US-7687527-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2010-03-30 | — | — | US | disclosed |
| US-7683085-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2010-03-23 | — | — | US | disclosed |
| US-20090170875-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION | 2009-07-02 | — | — | US | disclosed |
| US-20090137586-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION | 2009-05-28 | — | — | US | disclosed |
| US-20090111803-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION | 2009-04-30 | — | — | US | disclosed |
| US-7504424-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2009-03-17 | — | — | US | disclosed |
| US-7488745-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2009-02-10 | — | — | US | disclosed |
| US-7482370-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2009-01-27 | — | — | US | disclosed |
| US-20070219218-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2007-09-20 | — | — | US | disclosed |
| US-20060276506-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2006-12-07 | — | — | US | disclosed |
| WO-2006019768-A1 | HYDANTOIN DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION (US) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111803-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TNF, MMP12, MMP8 | SYK 1123/4885MAPT 863/4885SMN1; SMN2 1473/4885 |
| US-20070219218-A1 | Compounds for the treatment of inflammatory disorders | ADAMTS1, ADAMTS13, ADAMTS7 | SYK 1914/4885MAPT 641/4885SMN1; SMN2 1225/4885 |
| US-20090170875-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | ADAMTS1, ADAMTS13, ADAMTS7 | SYK 1914/4885MAPT 641/4885SMN1; SMN2 1225/4885 |
| US-20090137586-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | ADAMTS1, ADAMTS13, ADAMTS7 | SYK 1914/4885MAPT 641/4885SMN1; SMN2 1225/4885 |
| US-20060276506-A1 | Compounds for the treatment of inflammatory disorders | ADAMTS1, ADAMTS13, ADAMTS7 | SYK 1914/4885MAPT 641/4885SMN1; SMN2 1225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.